Actinium Pharmaceuticals
ATNMClinical Pipeline
Program / Asset
Target Indications
Development Phase
Financial Statements & Analysis
Total Gross Revenue
— $0.09M $0.09M —
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
($4.88M) ($4.25M) ($21.12M) ($4.20M)
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($2.62M) ($1.53M) ($15.21M) ($1.70M)
Operating Income / (Loss)
($7.50M) ($5.69M) ($36.25M) ($5.90M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
$0.63M $0.56M $2.36M $0.38M
Interest & Debt Servicing Expense
— — — —
Other Non-Operating Income / (Expense)
$0.63M $0.56M $2.36M $0.38M
Income Tax Provision / (Benefit)
— — — —
NET INCOME / (NET LOSS)
($6.88M) ($5.13M) ($33.89M) ($5.52M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$59.9M$53.4M$48.0M$42.1M
Short-Term Marketable Investments
// --// --// --// --
Total Liquid Cash Resources
$59.9M$53.4M$48.0M$42.1M
Accounts Receivable, Net
// --// --// --// --
Prepaid Expenses & Other Current Assets
$1.1M$1.0M$1.4M$1.1M
Total Current Assets
$61.0M$54.4M$49.4M$43.3M
Property, Plant and Equipment, Net
$0.3M$0.2M$0.3M$0.3M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$63.0M$56.2M$51.8M$45.4M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
// --// --// --// --
Accrued Expenses & Clinical Liabilities
// --// --// --// --
Total Current Liabilities
$8.3M$6.8M$8.0M$7.3M
Long-Term Corporate Debt Balances
// --// --// --// --
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$35.7M$35.5M$36.0M$35.8M
Total Liabilities Block
$44.0M$42.4M$43.9M$43.1M
Total Stockholders' Equity
$19.0M$13.8M$7.8M$2.3M
TOTAL LIABILITIES & EQUITY
$63.0M$56.2M$51.8M$45.4M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
7.34x 7.96x 6.20x 5.89x
R&D Expenditure Flow
$12.6M$16.8M$21.1M$4.2M
Net Income / (Loss)
($6.88M) ($5.13M) ($33.89M) ($5.52M)
Depreciation & Amortization
$0.41M $0.61M $0.17M $0.03M
Stock-Based Compensation
$9.07M $9.18M $9.19M $0.01M
Change in Accounts Receivable
— — — —
Change in Prepaid Assets / Expenses
($0.50M) ($0.63M) ($0.22M) ($0.25M)
Change in Payables & Clinical Accruals
$0.15M ($1.34M) ($0.35M) ($0.66M)
Other Operating Source / (Use) Changes
($15.21M) ($21.98M) $0.51M $0.53M
Net Cash from Operating Activities
($12.97M) ($19.29M) ($24.58M) ($5.87M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
— — ($0.10M) ($0.00M)
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
— — — —
Net Cash from Investing Activities
— — ($0.10M) ($0.00M)
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
— — — —
Net Cash from Financing Activities
($0.01M) ($0.21M) ($0.22M) ($0.00M)
NET CONSOLIDATED CHANGE IN CASH
— — ($24.89M) ($5.86M)
Clinical Trials Registry
Registry ID
Phase / Asset
Status
NCT06768905
P-1 — Iomab-ACT
recruiting
NCT04512716
EARLY_P-1 — Iomab-ACT
recruiting
NCT02665065
P-3 — Iomab-B
active not
NCT07157514
P-2 — Iomab-B
not yet rec
NCT00589316
P-1 — Iomab-B
terminated
NCT03705858
P-1 — Lintuzumab-Ac225
withdrawn
NCT02575963
P-1 — Lintuzumab-Ac225
completed
NCT06802523
P-1 — Lintuzumab-Ac225
suspended
NCT06888323
P-1 — Lintuzumab-Ac225
suspended
NCT03867682
P-1 — Lintuzumab-Ac225
unknown
NCT07422363
P-1 — Lintuzumab-Ac225
not yet rec
NCT03932318
P-1 — Lintuzumab-Ac225
withdrawn
NCT03441048
P-1 — Lintuzumab-Ac225
completed